메뉴 건너뛰기




Volumn 26, Issue 18, 2016, Pages 4387-4393

Recent progress on nuclear receptor RORγ modulators

Author keywords

IL 17; RORc; ROR

Indexed keywords

INTERLEUKIN 17; RETINOID RELATED ORPHAN RECEPTOR GAMMA;

EID: 84983087609     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2016.08.012     Document Type: Review
Times cited : (76)

References (88)
  • 6
    • 85019801611 scopus 로고    scopus 로고
    • Nuclear Receptors as Drug Targets: A Historical Perspective of Modern Drug Discovery
    • E. Ottow H. Weinmann 1st ed. Wiley-VCH Verlag GmbH & Co. KGaA Weinheim, Germany
    • 6 Ottow, E., Weinmann, H., Nuclear Receptors as Drug Targets: A Historical Perspective of Modern Drug Discovery. Ottow, E., Weinmann, H., (eds.) Nuclear Drug Receptors as Targets, 1st ed., 2008, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 1–17.
    • (2008) Nuclear Drug Receptors as Targets , pp. 1-17
    • Ottow, E.1    Weinmann, H.2
  • 13
    • 84983082895 scopus 로고    scopus 로고
    • The 25-hydroxycholesterol is represented with the same stereochemistry than reported in Ref. 12.
    • 13 The 25-hydroxycholesterol is represented with the same stereochemistry than reported in Ref. 12.
  • 19
    • 84905560898 scopus 로고    scopus 로고
    • 19 Dong, C., Cell Res., 24, 2014, 901.
    • (2014) Cell Res. , vol.24 , pp. 901
    • Dong, C.1
  • 22
    • 84983079232 scopus 로고    scopus 로고
    • Novartis press release: Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients, (accessed 23 February).
    • 22 Novartis press release: Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients, https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab (accessed 23 February 2016).
    • (2016)
  • 23
    • 84983021189 scopus 로고    scopus 로고
    • FDA approves new psoriasis drug Taltz, (accessed 28 March).
    • 23 FDA approves new psoriasis drug Taltz, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491872.htm (accessed 28 March 2016).
    • (2016)
  • 40
    • 84983085676 scopus 로고    scopus 로고
    • Fierce Biotech article: Eyeing buyout, Celgene paying $105M to partner on Lycera's anti-cancer T cell tech, (accessed 27 July).
    • 40 Fierce Biotech article: Eyeing buyout, Celgene paying $105M to partner on Lycera's anti-cancer T cell tech, http://www.fiercebiotech.com/partnering/eyeing-buyout-celgene-paying-105m-to-partner-on-lycera-s-anti-cancer-t-cell-tech (accessed 27 July 2016).
    • (2016)
  • 45
    • 84983027432 scopus 로고    scopus 로고
    • Study of Safety and Efficacy of Topical GSK2981278 in Plaque Psoriasis, (accessed 18 March).
    • 45 Study of Safety and Efficacy of Topical GSK2981278 in Plaque Psoriasis, https://clinicaltrials.gov/ct2/show/NCT02548052?term=GSK2981278&rank=1 (accessed 18 March 2016).
    • (2016)
  • 46
    • 84983065351 scopus 로고    scopus 로고
    • Drug Profile GSK 2981278, (accessed 18 March).
    • 46 Drug Profile GSK 2981278, http://adisinsight.springer.com/drugs/800043256 (accessed 18 March 2016).
    • (2016)
  • 64
    • 84983042055 scopus 로고    scopus 로고
    • Vitae Pharmaceuticals press release: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORγt Inhibitor in Mild to Severe Psoriasis, (accessed 29 March).
    • 64 Vitae Pharmaceuticals press release: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORγt Inhibitor in Mild to Severe Psoriasis, http://ir.vitaepharma.com/phoenix.zhtml?c=219654&p=irol-newsArticle&ID=2149044 (accessed 29 March 2016).
    • (2016)
  • 65
    • 84983027413 scopus 로고    scopus 로고
    • An ascending multiple dose study with VTP-43742 in healthy volunteers and psoriatic patients, (accessed 29 March).
    • 65 An ascending multiple dose study with VTP-43742 in healthy volunteers and psoriatic patients, https://clinicaltrials.gov/ct2/show/NCT02555709?term=VTP-43742&rank=1 (accessed 29 March 2016).
    • (2016)
  • 72
    • 84983029172 scopus 로고    scopus 로고
    • Search results on clinicaltrials.gov for: Japan Tobacco, (accessed 14th March).
    • 72 Search results on clinicaltrials.gov for: Japan Tobacco, https://clinicaltrials.gov/ct2/results?term=japan+tobacco&Search=Search (accessed 14th March 2016).
    • (2016)
  • 73
    • 84983051094 scopus 로고    scopus 로고
    • Japan Tobacco clinical development, (accessed 27 July).
    • 73 Japan Tobacco clinical development, https://www.jt.com/investors/results/S_information/pharmaceuticals/pdf/20160502_11.pdf (accessed 27 July 2016).
    • (2016)
  • 75
    • 84983092932 scopus 로고    scopus 로고
    • Arrien Pharmaceuticals news and scientific events, (accessed 26 May).
    • 75 Arrien Pharmaceuticals news and scientific events, http://www.arrienpharma.com/news.php (accessed 26 May 2016).
    • (2016)
  • 85
    • 84983056175 scopus 로고    scopus 로고
    • Takeda pipeline, (accessed 27 July).
    • 85 Takeda pipeline, http://www.takeda.com/research/files/pipeline_20160510_en.pdf (accessed 27 July 2016).
    • (2016)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.